113 related articles for article (PubMed ID: 21557219)
1. Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is 'too big to fail'.
Castellani RJ; Smith MA
J Pathol; 2011 Jun; 224(2):147-52. PubMed ID: 21557219
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here?
Saxena U
Expert Opin Ther Targets; 2010 Dec; 14(12):1273-7. PubMed ID: 21058918
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease 2012: the great amyloid gamble.
Marchesi VT
Am J Pathol; 2012 May; 180(5):1762-7. PubMed ID: 22472273
[TBL] [Abstract][Full Text] [Related]
4. Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment.
Buchhave P; Zetterberg H; Blennow K; Minthon L; Janciauskiene S; Hansson O
Neurobiol Aging; 2010 Nov; 31(11):1877-84. PubMed ID: 19070941
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
Roy S; Rauk A
Med Hypotheses; 2005; 65(1):123-37. PubMed ID: 15893129
[TBL] [Abstract][Full Text] [Related]
6. Larger temporal volume in elderly with high versus low beta-amyloid deposition.
Chételat G; Villemagne VL; Pike KE; Baron JC; Bourgeat P; Jones G; Faux NG; Ellis KA; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
Brain; 2010 Nov; 133(11):3349-58. PubMed ID: 20739349
[TBL] [Abstract][Full Text] [Related]
7. Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease.
Bossers K; Wirz KT; Meerhoff GF; Essing AH; van Dongen JW; Houba P; Kruse CG; Verhaagen J; Swaab DF
Brain; 2010 Dec; 133(Pt 12):3699-723. PubMed ID: 20889584
[TBL] [Abstract][Full Text] [Related]
8. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
Tomiyama T
Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
[TBL] [Abstract][Full Text] [Related]
9. [Molecular actors in Alzheimer's disease: which diagnostic and therapeutic consequences?].
Buée L; Blum D; Bombois S; Buée-Scherrer V; Caillet-Boudin ML; Colin M; Deramecourt V; Dhaenens CM; Galas MC; Hamdane M; Humez S; Maurage CA; Pasquier F; Sablonnière B; Schraen-Maschke S; Sergeant N
Therapie; 2010; 65(5):401-7. PubMed ID: 21144474
[TBL] [Abstract][Full Text] [Related]
10. Amyloid imaging in Alzheimer's disease.
Nordberg A
Neuropsychologia; 2008; 46(6):1636-41. PubMed ID: 18468648
[TBL] [Abstract][Full Text] [Related]
11. Differential damage in the frontal cortex with aging, sporadic and familial Alzheimer's disease.
Leuba G; Vernay A; Zimmermann V; Saini K; Kraftsik R; Savioz A
Brain Res Bull; 2009 Oct; 80(4-5):196-202. PubMed ID: 19559767
[TBL] [Abstract][Full Text] [Related]
12. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade.
Wirths O; Multhaup G; Bayer TA
J Neurochem; 2004 Nov; 91(3):513-20. PubMed ID: 15485483
[TBL] [Abstract][Full Text] [Related]
13. [Perspectives on the amyloid cascade hypothesis of Alzheimer's disease].
Simón AM; Frechilla D; del Río J
Rev Neurol; 2010 Jun; 50(11):667-75. PubMed ID: 20514639
[TBL] [Abstract][Full Text] [Related]
14. Olfactory tau pathology in Alzheimer disease and mild cognitive impairment.
Attems J; Jellinger KA
Clin Neuropathol; 2006; 25(6):265-71. PubMed ID: 17140156
[TBL] [Abstract][Full Text] [Related]
15. Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.
Donohue MC; Gamst AC; Aisen PS
Alzheimers Dement; 2011 Mar; 7(2):245-6; author reply 247-9. PubMed ID: 21414558
[No Abstract] [Full Text] [Related]
16. Low-n oligomers as therapeutic targets of Alzheimer's disease.
Ono K; Yamada M
J Neurochem; 2011 Apr; 117(1):19-28. PubMed ID: 21244429
[TBL] [Abstract][Full Text] [Related]
17. Development of retro-inverso peptides as anti-aggregation drugs for β-amyloid in Alzheimer's disease.
Matharu B; El-Agnaf O; Razvi A; Austen BM
Peptides; 2010 Oct; 31(10):1866-72. PubMed ID: 20633587
[TBL] [Abstract][Full Text] [Related]
18. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease.
Boissonneault V; Filali M; Lessard M; Relton J; Wong G; Rivest S
Brain; 2009 Apr; 132(Pt 4):1078-92. PubMed ID: 19151372
[TBL] [Abstract][Full Text] [Related]
19. N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers.
Decker H; Jürgensen S; Adrover MF; Brito-Moreira J; Bomfim TR; Klein WL; Epstein AL; De Felice FG; Jerusalinsky D; Ferreira ST
J Neurochem; 2010 Dec; 115(6):1520-9. PubMed ID: 20950339
[TBL] [Abstract][Full Text] [Related]
20. A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment.
Leon WC; Canneva F; Partridge V; Allard S; Ferretti MT; DeWilde A; Vercauteren F; Atifeh R; Ducatenzeiler A; Klein W; Szyf M; Alhonen L; Cuello AC
J Alzheimers Dis; 2010; 20(1):113-26. PubMed ID: 20164597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
